Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Daniel Engelbertsen

Assistant researcher

Default user image.

Expansion of CD25+ Innate Lymphoid Cells Reduces Atherosclerosis

Author

  • Daniel Engelbertsen
  • Amanda C. Foks
  • Noah Alberts-Grill
  • Felicia Kuperwaser
  • Tao Chen
  • James A. Lederer
  • Petr Jarolim
  • Nir Grabie
  • Andrew H. Lichtman

Summary, in English

Innate lymphoid cells (ILCs) are a newly discovered subset of immune cells that promote tissue homeostasis and protect against pathogens. ILCs produce cytokines also produced by T lymphocytes that have been shown to affect atherosclerosis, but the influence of ILCs on atherosclerosis has not been explored. Approach and Results-We demonstrate that CD25+ ILCs that produce type 2 cytokines (ILC2s) are present in the aorta of atherosclerotic immunodeficient ldlr-/-rag1-/- mice. To investigate the role of ILCs in atherosclerosis, ldlr-/-rag1-/- mice were concurrently fed an atherogenic diet and treated with either ILC-depleting anti-CD90.2 antibodies or IL-2/anti-IL-2 complexes that expand CD25+ ILCs. Lesion development was not affected by anti-CD90.2 treatment, but was reduced in IL-2/anti-IL-2-treated mice. These IL-2-treated mice had reduced very low-density lipoprotein cholesterol and increased triglycerides compared with controls and reduced apolipoprotein B100 gene expression in the liver. IL-2/anti-IL-2 treatment caused expansion of ILC2s in aorta and other tissues, elevated levels of IL-5, systemic eosinophila, and hepatic eosinophilic inflammation. Blockade of IL-5 reversed the IL-2 complex-induced eosinophilia but did not change lesion size. Conclusions-This study demonstrates that expansion of CD25-expressing ILCs by IL-2/anti-IL-2 complexes leads to a reduction in very low-density lipoprotein cholesterol and atherosclerosis. Global depletion of ILCs by anti-CD90.2 did not significantly affect lesion size indicating that different ILC subsets may have divergent effects on atherosclerosis.

Publishing year

2015-12-01

Language

English

Pages

2526-2535

Publication/Series

Arteriosclerosis, Thrombosis, and Vascular Biology

Volume

35

Issue

12

Document type

Journal article

Publisher

Lippincott Williams & Wilkins

Topic

  • Immunology in the medical area

Keywords

  • Atherosclerosis
  • cytokines
  • eosinophils
  • interleukin
  • triglycerides

Status

Published

ISBN/ISSN/Other

  • ISSN: 1079-5642